Table 5. Subgroup analysis for survival data.
| Subgroup analysis for survival data | ||||
|---|---|---|---|---|
| Outcome | Subgroup | Trials | HR M-H, Fixed, 95%CI, P value | Heterogeneity I², P value |
| OS according to age in Group 1 | 15–65 years old | 3 | 0.76[0.65,0.88]p = 0.0003 | 0%,p = 0.79 |
| 65–83 years old | 1 | 1.09[0.92,1.31]p = 0.32 | not applicable | |
| OS according to cytogenetic risk in Group 1 | favorable risk | 2 | 0.85[0.44,1.64]p = 0.62 | 68%,p = 0.08 |
| intermediate risk | 2 | 0.87[0.71,1.06]p = 0.16 | 57%,p = 0.13 | |
| unfavorable risk | 3 | 0.83[0.70,0.97]p = 0.02 | 48%,p = 0.15 | |
| EFS according to cytogenetic risk in Group 1 | favorable risk | 2 | 0.85[0.47,1.53]p = 0.59 | 63%,p = 0.10 |
| intermediate risk | 2 | 0.90[0.76,1.07]p = 0.24 | 62%,p = 0.10 | |
| unfavorable risk | 2 | 0.66[0.45,0.97]p = 0.04 | 0%,p = 0.35 | |
| DFS according to cytogenetic risk in Group 1 | favorable risk | 2 | 1.52[1.00,2.30]p = 0.05 | 75%,p = 0.04 |
| intermediate risk | 2 | 0.93[0.76,1.15]p = 0.53 | 67%,p = 0.08 | |
| unfavorable risk | 2 | 0.84[0.51,1.38]p = 0.49 | 48%,p = 0.16 | |
OS, overall survival; DFS, disease-free survival; EFS, event-free survival
Group 1, high doses of daunorubicin vs. low doses of daunorubicin
Group 2, high doses of daunorubicin vs. Idarubicin
HR, hazard ratio; M–H, Mantel–Haenszel method; Fixed, fixed-effect model; CI, confidence interval.